Tilt Biotherapeutics raised €22M in a Series B round in May 2025. The company is based in Helsinki, Finland. Investors in the round: European Innovation Council (EIC) Fund, Finnish Industry Investment (Tesi), Lifeline Ventures and 1 other. Data as of 7 Aug 2026.
Confidence is the weaker of amount-FX and source evidence (the cascade rule). See methodology.
